Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of spinal muscular atrophy by sodium butyrate.

Proceedings of the National Academy of Sciences of the United States of America - 14 Aug 2001

Chang J G, Hsieh-Li H M, Jong Y J, Wang N M, Tsai C H, Li H

Abstract excerpt

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, leading to muscular paralysis with muscular atrophy. No effective treatment of this disorder is presently available. Studies of the correlation between disease severity and the amount of survival motor neuron (SMN) protein have shown an inverse relationship. We report that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butyrates
Share to Cyclic AMP Response Element-Binding Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Diseases

Share to Maternal-Fetal Exchange

Share to Okadaic Acid

Share to SMN Complex Proteins

Share to Survival of Motor Neuron 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 11504946
DOI: 10.1073/pnas.171105098
PMCID: PMC55534

Genes

SMN2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of spinal muscular atrophy by sodium butyrate.PMID 11504946Read ↗

Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy.Semantic proximity Read ↗

Spinal muscular atrophy: from gene to therapy.Semantic proximity Read ↗

Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.Semantic proximity Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular AtrophySemantic proximity Read ↗

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophySemantic proximity Read ↗

Gene therapy: a promising approach to treating spinal muscular atrophy.Semantic proximity Read ↗

Valproic acid increases SMN levels in spinal muscular atrophy patient cellsSemantic proximity Read ↗

Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy.Semantic proximity Read ↗

Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model.Semantic proximity Read ↗

Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.Semantic proximity Read ↗

Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.